Shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) dropped 2.7% on Thursday . The company traded as low as $8.50 and last traded at $8.54, with a volume of 59,818 shares trading hands. The stock had previously closed at $8.78.

ADAP has been the topic of a number of research analyst reports. Leerink Swann restated a “buy” rating on shares of Adaptimmune Therapeutics PLC – in a research report on Friday, April 8th. Zacks Investment Research upgraded shares of Adaptimmune Therapeutics PLC – from a “hold” rating to a “buy” rating and set a $9.75 target price on the stock in a research report on Tuesday, July 12th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $15.94.

The stock’s 50-day moving average is $8.38 and its 200-day moving average is $8.65. The firm’s market capitalization is $600.26 million.

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) last posted its earnings results on Thursday, May 12th. The company reported ($0.22) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.03. On average, analysts forecast that Adaptimmune Therapeutics PLC – will post ($1.12) EPS for the current fiscal year.

In other news, Director Orbimed Advisors Llc bought 1,712,400 shares of the firm’s stock in a transaction that occurred on Tuesday, May 24th. The shares were acquired at an average price of $10.42 per share, with a total value of $17,843,208.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Charles Elliott Sigal bought 45,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 18th. The shares were purchased at an average cost of $1.53 per share, for a total transaction of $68,850.00. Following the acquisition, the director now directly owns 52,938 shares in the company, valued at approximately $80,995.14. The disclosure for this purchase can be found here.

A hedge fund recently bought a new stake in Adaptimmune Therapeutics PLC – stock. Marshall Wace LLP purchased a new position in Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 140,983 shares of the company’s stock, valued at approximately $1,700,000. Marshall Wace LLP owned about 0.20% of Adaptimmune Therapeutics PLC – at the end of the most recent reporting period.

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.